Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Roche Tecentriq,...

    Roche Tecentriq, chemotherapy combo wins USFDA approval for treatment of lung cancer

    Farhat NasimWritten by Farhat Nasim Published On 2019-03-19T09:30:09+05:30  |  Updated On 19 March 2019 9:30 AM IST
    Roche Tecentriq, chemotherapy combo wins USFDA approval for treatment of lung cancer

    New Delhi: Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb.


    The U.S. Food and Drug Administration (FDA) approved Tecentriq plus chemotherapy for untreated extensive-stage small cell lung cancer (SCLC) after a study showed patients getting the drug cocktail lived a median 12.3 months, compared to 10.3 months for those getting chemotherapy alone, Genentech said in a statement.


    Read Also: Pfizer biosimilar to Roche Herceptin wins USFDA nod


    About 10 to 15 per cent of lung cancers are small cell, or oat cell cancer, where tumours tend to spread very early. Advances in SCLC treatment have been slow in coming, and Roche has hailed Tecentriq as the first potential new first-line option in two decades.


    The FDA's decision on Monday follows approval of Tecentriq combinations in recent weeks for triple negative breast cancer and non-small cell lung cancer.


    Read Also: Roche to buy Spark Therapeutics in Rs 430 crore deal


    Tecentriq's 2018 revenue were 772 million Swiss francs ($766 million), compared with $7.2 billion for Merck's Keytruda immunotherapy and $6.7 billion for Bristol's Opdivo.


    The two rival drugs that harness the body's own immune system to fight disease had a roughly two-year head start on Roche's drug, which along with mounting data underscoring their effectiveness for some patients with different cancers has helped them gain a big lead in sales.


    Read Also: Roche, AC Immune drop Alzheimer drug trials after setback


    Opdivo is already approved in small cell lung cancer in cases where patients fail at least two other treatments, while Keytruda is now under priority FDA review, also for third-line treatment of SCLC.

    Bristol-Myers Squibbcancercancer treatmentchemotherapyFDAGenentechimmunotherapy TecentriqKeytruda immunotherapylung cancer treatmentMerck & CoOpdivoRocheRoche's drugSCLCSmall cell carcinomasmall-cell lung cancerSwiss drugmaker RocheTecentriqTecentriq plusUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok